Epilepsy Market Research Report - Global Forecast till 2027

Epilepsy Market Research Report: By Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), By Diagnosis & Treatment (Diagnosis & Treatment), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others) - Forecast till 2027

ID: MRFR/HC/6261-CR | February, 2021 | Region : Global

Epilepsy Market Overview


According to MRFR, the Epilepsy Market is slated to acquire USD 9.50 Billion valuation by 2023, exhibiting a CAGR of 8.20% over the assessment period (2018-2023). The increasing rate of epilepsy prevalence in the geriatric community and the rise in accident-induced brain injury cases are major factors driving market growth.


COVID-19 Analysis


The new coronavirus has spread worldwide in a relatively short period and has become a pandemic. Many affected patients have symptoms such as dry cough, tiredness, dyspnea, and fever. However, the infection with Covid-19 disrupts multiple tissues, including the kidney, liver, and nervous system. Common neurological symptoms of Covid-19 infection include delirium, depression, fever, and loss of smell and taste. It can cause stroke and epilepsy in rare cases. This has risen the demand for efficient epilepsy cures and medications. Moreover, the growing R&D investments towards COVID 19 treatments may also contribute towards the epilepsy market growth.


Market Dynamics


Increasing Incidence of PTE to Drive Market Growth


The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand. In addition, brain damage that can cause post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can fuel demand in the epilepsy industry. The worldwide demand for epilepsy is also influenced epilepsy market by primary factors such as developing experimental medicines, the arrival of new drugs in developed regions and the prevalence of neurological disorders such as meningitis and tumors. This rise is further fueled by an improvement in healthcare prices and an increase in disposable income.


Market Opportunities


Growing Adoption Of Advanced Imaging Technology For Early Diagnosis Contributes To Market Growth


Emerging trends such as businesses focused on designing innovative treatments for refractory epilepsy and doctors requiring higher effectiveness medications is increasing the R&D investments towards the epilepsy market. The growing adoption of rational polytherapy and the advanced imaging technology for early diagnosis also contributes to market growth. Moreover, the adoption of advanced digital healthcare models such as mHealth and telemedicine is likely to create growth opportunities for the epilepsy market.


Market Restraints


Rise in Medication Costs Likely to Impede Market Growth


On the other hand, the demand expansion is hampered by a time-consuming prescription approval process, and rising medication costs. Moreover, the low awareness about the challenges of epilepsy can also hinder the epilepsy market growth. Infact, consumers are increasingly petitioning gaming companies and social media platforms to include epileptic warnings.


Segment Overview


The research report segments the global market for epilepsy by disorder, diagnosis & care and end-use.


By Condition


By condition, the epilepsy market is bifurcated into epilepsy drug-resistant/intractable epilepsy and others. The drug-resistant epilepsy segment is expected to hit a value of USD 2.93 billion by the end of the forecast period. The advent of rational polytherapy for treating disease with minimal side-effects is expected to produce substantial revenue for the epilepsy market.


By Diagnosis and Treatment


By diagnosis and treatment, the epilepsy market for epilepsy is segmented into diagnosis and treatment. The treatment category is expected to drive the epilepsy market at a 7.91 percent CAGR during the projected period due to the availability of inexpensive medications to treat partial epileptic seizures. In addition, the approval of successful drugs by regulatory authorities will promote the development of the segment. On the other hand, the diagnostic segment is expected to mature at 8.76 percent CAGR over the evaluation period. The use of numerous imaging tests and blood tests to diagnose early on the condition is expected to accelerate segment development tenfold. 


By End-Use


Based on the end-users, the epilepsy market is segmented into hospitals, clinics, diagnostic centers, ambulatory surgical centers, and others. The hospital segment is touted to dominate the market growth over the review period, followed by the clinics segment. Moreover, hospitals that encourage the procurement of medicine from hospital premises are likely to promote the market.


Regional Analysis


The epilepsy industry in the region is segmented into the Americas, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA).


North America Dominates the Market with Superior Healthcare Infrastructure


Among them, the Americas accounted for 41 percent of the share in 2017, led by Europe, APAC, and MEA. North America is a leading contributor to the market due to the availability of well-established healthcare facilities, beneficial government policies aimed at strengthening the healthcare sector, and the presence of substantial research and development programs.


Growing R&D Investments Drive the Europe Market


Europe is expected to have a CAGR of 8.31% over the projected period. Increased investment in research and production of successful medications to cure epilepsy coupled with a high prevalence of the disease is expected to fuel regional demand exponentially.


Development of Novel Drugs to Raise APAC Market Scope


The APAC epilepsy market is set to reach a value of USD 2.04 million by 2023 due to the high occurrence of condition reported in the country. Also, the countries of India, South Korea and China, which are emerging as viable destinations for researching and producing novel products, will stimulate consumer demand over the forecast period.


Competitive Landscape


Production of efficient drugs and rising product approvals to be the primary tactics adopted by leading players


Companies active in the epilepsy therapeutics industry plan to strengthen their global reach through authorization by government agencies, partnerships, strategic mergers & acquisitions with other epilepsy market leaders in their respective territories and regions around the world. In order to strengthen their position in the global market for epilepsy therapeutics, robust progressive research and development efforts and product pipelines and growing product approvals are crucial strategies followed by these players. To increase their market share, most of the major players are engaged in reinforcing their product portfolio. It is predicted that the launch of new medicines would facilitate the market expansion of anti-epileptic medication.


December 2020: European CNS Specialist acquired Medinutrix Ltd to provide an immediate platform for the recently acquired market-leading epilepsy treatment 'Buccolam' in Ireland.


Key Players




  • LivaNova PLC (U.K.)




  • GlaxoSmithKline PLC (U.K.)




  • Eisai Co. Ltd. (Japan)




  • Pfizer Inc. (U.S.)




  • Medtronic PLC (Ireland)




  • UCB SA (Belgium)




  • NeuroPace Inc. (U.S.)




  • GW Pharmaceuticals PLC (U.K.)




  • Novartis AG (Switzerland)




  • Johnson & Johnson Services Inc. (U.S.)




  • Abbott Laboratories (U.S.)




Recent Developments


December 2020: The testing of Cenobamate (Xcopri), a new epilepsy drug showed positive results, where an open-label trial found that the incidence of seizures was substantially decreased and that among 240 adult patients who obtained cenobamate, the seizure-freedom rate was significantly increased. The use of concomitant antiseizure drugs (ASMs) by patients was also limited, with little effect on effectiveness.


December 2020: A new, less invasive epilepsy laser surgery, dubbed LITT or laser interstitial thermal therapy, was proposed by the University of Alabama at Birmingham (UAB). For certain forms of epilepsy, it is a new technique to use a laser to destroy brain tissue that is causing seizures.


Report Overview


This report focuses on the growth of the global epilepsy therapeutics market and consists of an extensive executive summary, including a market snapshot that includes details about different segments of the market. It also offers an overview of market competitiveness in terms of geography and market share analysis by leading participants, providing a detailed analysis of the overall competitive situation emerging in the epilepsy therapeutic market. The study also offers knowledge and data analyses of the global market for its commodity, distribution channel, and regional segments.


Market Segmentation


By Condition




  • Epilepsy Drug Resistant/Intractable Epilepsy




  • Others




By Diagnosis and Treatment




  • Diagnosis




  • Treatment




By End-Use




  • Hospitals




  • Clinics




  • Ambulatory Surgical Centers




  • Diagnostic Centers




  • Others



1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 20

3.2 Scope of the Study 20

3.3 Assumptions & Limitations 20

3.3.1 Assumptions 20

3.3.2 Limitations 20

3.4 Market Structure 21

4 Research Methodology

4.1 Research Process 23

4.2 Primary Research 24

4.3 Secondary Research 25

4.4 Market Size Estimation 26

4.5 Forecast Model 26

5 Market Dynamics

5.1 Introduction 28

5.2 Drivers 29

5.2.1 Rising prevalence of epilepsy amongst the geriatric population 29

5.2.2 Increasing cases of brain injuries due to road accidents 29

5.2.3 Rising neurological disorders 29

5.2.4 Increasing research funding in epilepsy 29

5.3 Restraints 30

5.3.1 Loss of patent protection for branded drugs 30

5.3.2 High costs associated with the treatment of epilepsy 30

5.4 Opportunities 30

5.4.1 Entering developing economies 30

6 Market Factor Analysis

6.1 Porter’s Five Forces Analysis 32

6.1.1 Bargaining Power of Suppliers 32

6.1.2 Bargaining Power of Buyers 33

6.1.3 Threat of New Entrants 33

6.1.4 Threat of Substitutes 33

6.1.5 Intensity of Rivalry 33

6.2 Supply Chain Analysis 34

6.2.1 R&D 34

6.2.2 Manufacturing 34

6.2.3 Distribution 34

6.2.4 Marketing & Sales 34

6.2.5 Post-Sales Monitoring 35

6.3 Investment Opportunities 35

6.4 Pricing Analysis 35

6.5 Demographic Analysis 36

7 Epilepsy Market, by Condition

7.1 Overview 39

7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy 41

7.1.2 Others 41

8 Epilepsy Market, by Diagnosis & Treatment

8.1 Overview 43

8.1.1 Diagnosis & Treatment 45

9 Epilepsy Market, by End User

9.1 Overview 50

10 Global Epilepsy Market, by Region

10.1 Overview 56

10.2 Americas 59

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1 North America 64

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1.1 US 68

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1.2 CANADA 72

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2 Latin America 75

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2.1 BRAZIL 79

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2.2 REST OF LATIN AMERICA 83

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3 Europe 87

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1 Western Europe 92

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.1 Germany 96

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.2 France 100

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.3 UK 103

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.2 Italy 107

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.3 Spain 110

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.4 Rest of Western Europe 114

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.5 Eastern Europe 117

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4 Asia-Pacific 121

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.1.1 Japan 126

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.1.2 China 130

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.2 India 134

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.3 Australia 137

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.4 South Korea 141

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.5 Rest of Asia-Pacific 144

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.5 Middle East & Africa 148

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6 Middle East 153

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.1.1 Saudi Arabia 157

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.1.2 Rest of Middle East 160

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.2 Africa 164

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

11 Competitive Landscape

11.1 Company Market Share Analysis 169

11.1.1 Introduction 169

12 Company Profile

12.1 LivaNova PLC 172

12.1.1 Company Overview 172

12.1.2 Financial Overview 172

12.1.3 Products/Services Offered 173

12.1.4 Key Development 173

12.1.5 SWOT Analysis 173

12.1.6 Key Strategies 173

12.2 GlaxoSmithKline PLC 174

12.2.1 Company Overview 174

12.2.2 Financial Overview 174

12.2.3 Products/Services Offered 174

12.2.4 Key Development 175

12.2.5 SWOT Analysis 175

12.2.6 Key Strategies 175

12.3 Eisai Co. Ltd 176

12.3.1 Company Overview 176

12.3.2 Financial Overview 176

12.3.3 Products/Services Offered 176

12.3.4 Key Development 177

12.3.5 SWOT Analysis 177

12.3.6 Key Strategies 177

12.4 Pfizer Inc 178

12.4.1 Company Overview 178

12.4.2 Financial Overview 178

12.4.3 Products/Services Offered 178

12.4.4 Key Developments 179

12.4.5 SWOT Analysis 179

12.4.6 Key Strategies 179

12.5 Medtronic PLC 180

12.5.1 Company Overview 180

12.5.2 Financial Overview 180

12.5.3 Products/Services Offered 181

12.5.4 Key Developments 181

12.5.5 SWOT Analysis 181

12.5.6 Key Strategies 181

12.6 UCB SA 182

12.6.1 Company Overview 182

12.6.2 Financial Overview 182

12.6.3 Products/Services Offered 183

12.6.4 Key Developments 183

12.6.5 SWOT Analysis 183

12.6.6 Key Strategies 183

12.7 NeuroPace Inc 184

12.7.1 Company Overview 184

12.7.2 Financial Overview 184

12.7.3 Products/Services Offered 184

12.7.4 Key Developments 184

12.7.5 SWOT Analysis 184

12.7.6 Key Strategies 184

12.8 GW Pharmaceuticals PLC 185

12.8.1 Company Overview 185

12.8.2 Financial Overview 185

12.8.3 Products/Services Offered 185

12.8.4 Key Developments 186

12.8.5 SWOT Analysis 186

12.8.6 Key Strategies 186

12.9 Novartis AG 187

12.9.1 Company Overview 187

12.9.2 Financial Overview 187

12.9.3 Products/Services Offered 187

12.9.4 Key Developments 188

12.9.5 SWOT Analysis 188

12.9.6 Key Strategies 188

12.10 Johnson & Johnson Services Inc. 189

12.10.1 Company Overview 189

12.10.2 Financial Overview 189

12.10.3 Products/Services Offered 189

12.10.4 Key Developments 190

12.10.5 SWOT Analysis 190

12.10.6 Key Strategies 190

12.11 Abbott Laboratories 191

12.11.1 Company Overview 191

12.11.2 Financial Overview 191

12.11.3 Products/Services Offered 191

12.11.4 Key Developments 192

12.11.5 SWOT Analysis 192

12.11.6 Key Strategies 192

13 Appendix

13.1 Discussion Blue Print 194

14 List of Tables

TABLE 1 MARKET SYNOPSIS 18

TABLE 2 PRIMARY INTERVIEWS 23

TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 40

TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2020–2027 (USD MILLION) 41

TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2020–2027 (USD MILLION) 41

TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 45

TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 47

TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 47

TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 48

TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 48

TABLE 13 GLOBAL EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 14 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 52

TABLE 15 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY REGION 2020–2027 (USD MILLION) 52

TABLE 16 GLOBAL EPILEPSY MARKET, FOR CLINICS (FAMILY PRACTITIONERS/ INTERNAL MEDICINE), BY REGION 2020–2027 (USD MILLION) 53

TABLE 17 GLOBAL EPILEPSY MARKET, FOR AMBULATORY SURGICAL CENTERS (OUTPATIENT CENTERS), BY REGION 2020–2027 (USD MILLION) 53

TABLE 18 GLOBAL EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 54

TABLE 19 GLOBAL EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 20 GLOBAL PREVALENCE OF EPILEPSY 2020-2027 57

TABLE 21 GLOBAL INCIDENCE OF EPILEPSY 2020-2027 57

TABLE 22 AMERICAS: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 60

TABLE 23 AMERICAS: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 60

TABLE 24 AMERICAS: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 25 AMERICAS: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 61

TABLE 26 AMERICAS: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 61

TABLE 27 AMERICAS: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 28 AMERICAS: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 29 AMERICAS: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 30 AMERICAS: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 63

TABLE 31 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 32 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 64

TABLE 33 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 65

TABLE 34 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 65

TABLE 35 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 36 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 37 NORTH AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 38 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 39 NORTH AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 68

TABLE 40 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 68

TABLE 41 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 42 US: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 43 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 70

TABLE 44 US: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 70

TABLE 45 US: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 46 US: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 47 CANADA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 72

TABLE 48 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 72

TABLE 49 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 72

TABLE 50 CANADA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 51 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 52 CANADA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 74

TABLE 53 CANADA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 54 CANADA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 55 LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 75

TABLE 56 LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 57 LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 76

TABLE 58 LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 59 LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 78

TABLE 60 LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 61 LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 62 BRAZIL: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 79

TABLE 63 BRAZIL: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 64 BRAZIL: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 80

TABLE 65 BRAZIL: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 80

TABLE 66 BRAZIL: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 67 BRAZIL: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 68 BRAZIL: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 69 REST OF LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 83

TABLE 70 REST OF LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 83

TABLE 71 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 72 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 73 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 74 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 75 REST OF LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 76 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 77 EUROPE: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 88

TABLE 78 EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 88

TABLE 79 EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 80 EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 81 EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 82 EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 90

TABLE 83 EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 90

TABLE 84 EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 85 EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 91

TABLE 86 WESTERN EUROPE: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92

TABLE 87 WESTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 93

TABLE 88 WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 93

TABLE 89 WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 93

TABLE 90 WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 91 WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 92 WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 95

TABLE 93 WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 94 WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 96

TABLE 95 GERMANY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 96

TABLE 96 GERMANY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 97 GERMANY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 98 GERMANY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 98

TABLE 99 GERMANY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 98

TABLE 100 GERMANY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 101 GERMANY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 99

TABLE 102 FRANCE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 100

TABLE 103 FRANCE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100

TABLE 104 FRANCE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 100

TABLE 105 FRANCE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 106 FRANCE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 107 FRANCE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 102

TABLE 108 FRANCE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 102

TABLE 109 FRANCE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 103

TABLE 110 UK: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 103

TABLE 111 UK: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 103

TABLE 112 UK: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 104

TABLE 113 UK: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 104

TABLE 114 UK: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 115 UK: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 116 UK: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 117 UK: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 106

TABLE 118 ITALY: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 107

TABLE 119 ITALY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 107

TABLE 120 ITALY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 107

TABLE 121 ITALY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 108

TABLE 122 ITALY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 108

TABLE 123 ITALY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 109

TABLE 124 ITALY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 109

TABLE 125 ITALY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 110

TABLE 126 SPAIN: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 110

TABLE 127 SPAIN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 110

TABLE 128 SPAIN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 111

TABLE 129 SPAIN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 111

TABLE 130 SPAIN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 112

TABLE 131 SPAIN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 112

TABLE 132 SPAIN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 113

TABLE 133 SPAIN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 113

TABLE 134 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 114

TABLE 135 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 114

TABLE 136 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 115

TABLE 137 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 115

TABLE 138 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 116

TABLE 139 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 116

TABLE 140 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 117

TABLE 141 EASTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 117

TABLE 142 EASTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 117

TABLE 143 EASTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 118

TABLE 144 EASTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 118

TABLE 145 EASTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 119

TABLE 146 EASTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 119

TABLE 147 EASTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 120

TABLE 148 EASTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 120

TABLE 149 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122

TABLE 150 ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 122

TABLE 151 ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 123

TABLE 152 ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 123

TABLE 153 ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 124

TABLE 154 ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 124

TABLE 155 ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 125

TABLE 156 ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 125

TABLE 157 ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 126

TABLE 158 JAPAN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 127

TABLE 159 JAPAN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 127

TABLE 160 JAPAN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 128

TABLE 161 JAPAN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 128

TABLE 162 JAPAN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 129

TABLE 163 JAPAN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 129

TABLE 164 JAPAN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 130

TABLE 165 CHINA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 130

TABLE 166 CHINA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 131

TABLE 167 CHINA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 131

TABLE 168 CHINA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 132

TABLE 169 CHINA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 132

TABLE 170 CHINA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 133

TABLE 171 CHINA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 133

TABLE 172 INDIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 134

TABLE 173 INDIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 134

TABLE 174 INDIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 134

TABLE 175 INDIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 135

TABLE 176 INDIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 135

TABLE 177 INDIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 136

TABLE 178 INDIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 136

TABLE 179 INDIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 137

TABLE 180 AUSTRALIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 137

TABLE 181 AUSTRALIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 137

TABLE 182 AUSTRALIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 138

TABLE 183 AUSTRALIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 138

TABLE 184 AUSTRALIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 139

TABLE 185 AUSTRALIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 139

TABLE 186 AUSTRALIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 140

TABLE 187 AUSTRALIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 140

TABLE 188 SOUTH KOREA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 141

TABLE 189 SOUTH KOREA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 141

TABLE 190 SOUTH KOREA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 141

TABLE 191 SOUTH KOREA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 142

TABLE 192 SOUTH KOREA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 142

TABLE 193 SOUTH KOREA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 143

TABLE 194 SOUTH KOREA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 143

TABLE 195 SOUTH KOREA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 144

TABLE 196 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 144

TABLE 197 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 144

TABLE 198 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 145

TABLE 199 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 145

TABLE 200 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 146

TABLE 201 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 146

TABLE 202 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 147

TABLE 203 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 147

TABLE 204 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 149

TABLE 205 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 149

TABLE 206 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 149

TABLE 207 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 150

TABLE 208 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 150

TABLE 209 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 151

TABLE 210 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 151

TABLE 211 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 152

TABLE 212 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 152

TABLE 213 MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 153

TABLE 214 MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 153

TABLE 215 MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 154

TABLE 216 MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 154

TABLE 217 MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 155

TABLE 218 MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 155

TABLE 219 MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 156

TABLE 220 MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 156

TABLE 221 SAUDI ARABIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 157

TABLE 222 SAUDI ARABIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 157

TABLE 223 SAUDI ARABIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 157

TABLE 224 SAUDI ARABIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 158

TABLE 225 SAUDI ARABIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 158

TABLE 226 SAUDI ARABIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 159

TABLE 227 SAUDI ARABIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 159

TABLE 228 SAUDI ARABIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 160

TABLE 229 REST OF MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 160

TABLE 230 REST OF MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 160

TABLE 231 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 161

TABLE 232 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 161

TABLE 233 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 162

TABLE 234 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 162

TABLE 235 REST OF MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 163

TABLE 236 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 163

TABLE 237 AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 164

TABLE 238 AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 164

TABLE 239 AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 164

TABLE 240 AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 165

TABLE 241 AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 165

TABLE 242 AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 166

TABLE 243 AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 166

TABLE 244 AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 167


15 List of Figures

FIGURE 1 GLOBAL EPILEPSY MARKET: MARKET STRUCTURE 21

FIGURE 2 RESEARCH PROCESS 23

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 26

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL EPILEPSY MARKET 32

FIGURE 5 SUPPLY CHAIN: EPILEPSY MARKET 34

FIGURE 6 GLOBAL EPILEPSY MARKET SHARE, BY CONDITION, 2020 (%) 39

FIGURE 7 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020 & 2027 40

FIGURE 8 GLOBAL EPILEPSY MARKET SHARE, BY DIAGNOSIS & TREATMENT, 2020 (%) 44

FIGURE 9 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 45

FIGURE 10 GLOBAL EPILEPSY MARKET SHARE, BY END USER, 2020 (%) 50

FIGURE 11 GLOBAL EPILEPSY MARKET, BY END USER, 2020 & 2027 51

FIGURE 12 GLOBAL EPILEPSY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 56

FIGURE 13 GLOBAL EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 58

FIGURE 14 AMERICAS: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 59

FIGURE 15 NORTH AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 64

FIGURE 16 LATIN AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 75

FIGURE 17 EUROPE: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 87

FIGURE 18 WESTERN EUROPE: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 92

FIGURE 19 ASIA-PACIFIC: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 121

FIGURE 20 MIDDLE EAST AND AFRICA: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 148

FIGURE 21 MIDDLE EAST: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 153

FIGURE 22 GLOBAL EPILEPSY MARKET, MARKET SHARE ANALYSIS 2020 (%) 169

FIGURE 23 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE 2020 (%) 170



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Epilepsy Market